Table 1 Patient features

Patient’s features

 Age (years)

52

77

58

75

43

 Sex

Male

Female

Female

Male

Male

 Smoker status

Current

Former

Former

Former

Never smoke

 Comorbidity

Atrial fibrillation

Diabetes, hypertension, copd

Diabetes, hypertension, obesity

None

None

 BRAF status

Wild type

Wild type

Wild type

Wild type

V600E

 Melanoma type

Unknown origin

Cutaneous

Cutaneous

Unknown origin

Cutaneous

 M stage^a

M1d

M1a

M1b

M1b

M1a

 Tumor involvment

Lymphnodes, lung, brain

Soft tissues, lymphnodes

Soft tissues, lung

Lung

Sof tissue

Treatment features

 Treatment regimen

Nivolumab as 1° line

Pembrolizumab as 1° line

Pembrolizumab as 2° line

Nivolumab as 1° line

Ipilimumab plus nivolumab as 1° line

 Best response

Partial response

Partial response

Partial response

Partial response

Partial response

 Progression-free survival, months^b

12

24+

43+

26

8+

 OS, months^c

14+

24+

84+

36+

8+

Clinical features

 Onset (weeks)

8

44

88

60

6

 Clinical symptoms

dyspnoea, fatigue

dyspnoea, dry cough, fatigue

dyspnoea, fever, fatigue

dyspnoea, fatigue

dry cough, dyspnoea

 Grading irAE

G3

G4

G4

G3

G2

 Outcomes

Recovered

Subsequent recurrences

Subsequent recurrences

Recovered

Recovered

 Not lung toxicites

Skin (vitiligo)

Skin (vitiligo)

None

None

Gatrointestinal (colitis)

Blood tests

 PCO₂ mmHg

31

44

50

58

44

32–48

 PO₂ mmHg

41

69

71

61

88

83–108

 WBC (x 10³/μL)

17,2

13,4

11,8

16,9

7,8

4–10

 Neutrophils

11,4

8,5

9,6

11,2

5,07

1,7 –7,6

 Lymphocytes

4,8

4,06

1,3

5,2

2,1

1–3,2

 N/L

2,38

2,11

7,21

2,15

2,39

 LDH

>ULN

<ULN

<ULN

<ULN

<ULN

 Procalcitonin (ng/ml)

0,34

0,5

3,6

1,2

0,2

<2

CT scan

 CT scan pattern

NISP

COP

COP

NISP

COP

 Lung involvement

Upper and lower lobes

Upper and lower lobes

Mainly lower lobes

Upper and lower lobes

Mainly upper lobes